Vazyme

Executive Summary

Vazyme is a leading Chinese biotechnology company specializing in diagnostic reagents and instruments, with a core focus on enzymes, antibodies, and bio-reagents for clinical diagnostics and life science research. Founded in 2012 and headquartered in Nanjing, the company has grown to over 1,000 employees and achieved commercial stage with a public listing. Its comprehensive product portfolio spans molecular diagnostics, immunodiagnostics, and next-generation sequencing, positioning it as a key player in China's rapidly expanding in vitro diagnostics (IVD) market. The company's growth is driven by increasing demand for precision medicine and decentralized testing in China. Vazyme is expected to capitalize on its proprietary enzyme and antibody platforms to launch new diagnostic kits and expand into adjacent markets. Upcoming catalysts include potential NMPA approvals for novel molecular diagnostic panels and strategic partnerships for international expansion. With a strong R&D focus and favorable regulatory trends, Vazyme is well-positioned for sustained revenue growth.

Upcoming Catalysts (preview)

• Q3 2026NMPA approval of new multiplex respiratory pathogen panel80% success
• H2 2026Partnership with global diagnostics company for distribution in Southeast Asia60% success
• Q4 2026Launch of next-generation sequencing library preparation kit70% success